Model tests on single batter piles subjected to lateral soil movement

A series of laboratory tests have been carried out to investigate the lateral response of battered piles under lateral soil movement. Model tests were carried out using instrumented rigid aluminium piles. The piles were embedded in homogeneous sand soil at batter angles &beta = 0°, ±10° and ±20° were subjected to two types of lateral soil movement profile. The results obtained from the study are presented in terms of the bending moment, shear force, soil reaction, pile rotation and lateral deflections along the length of the batter pile. The results of model tests on single vertical and batter piles under horizontal loads showed that the batter angle (&beta) significantly influenced the response of the batter piles. Regardless of the value of sand density, bending moment and deflection with batter angles &beta = +10° or positive batter piles were higher compared then vertical piles and negative batter piles

Assessing the impact of velocity dip and wake coefficients on velocity prediction for open channel flows

The aim of the present study is to assess the impact of the velocity-dip and wake strength on the velocity prediction using the dip modified laws. The dip modified laws, particularly the dip modified log wake law (DMLW-law), are preferred over the traditional wall laws in the narrow open channels. This is mainly because these analytical-based laws basically rely on parameters for the velocity dip (α) caused by secondary flow and for the wake strength (Π) due to the turbulence and boundary walls. In this study, comprehensive expressions for estimating these two key parameters were proposed and tested for smooth and rough flows. The results indicated that the proposed expressions can noticeably improve the application of the DMLW-law model to both smooth and rough flow

Strategies for Sustainable Water Management: Hydrochemical Profiling and Protection Zone Design in Rania Basin, Iraq

Groundwater in the Rania basin, Iraqi Kurdistan region, has been under intensive exploitation in the last two decades, where quantity and quality are both affected. Hence, any attempt to protect the aquifers has become an urgent need. Saruchawa, Qulai Rania, and Qulai Kanimaran are the three large springs, among dozens of others in the area, that are heavily relied on as the sole or main source of water supply. Hydrochemical analysis, the first and most practical step to evaluating the water quality, was carried out through 60 water samples collected from 13 springs and 17 wells in both dry and wet seasons (October 2018 and May 2019). Laboratory results show a high calcium bicarbonate concentration with weak acids’ dominance. Protection zones are delineated for these springs using aquifer susceptibility to contamination and analysis of the recession part of the spring curves. The equivalent relationship between the protection factor (Fp) produced by the Epikarst, protective cover, infiltration condition, and Karst network development mapping method and the groundwater protection zone (S) is considered. Qulai Rania and Kanimaran Springs are mapped to be in S2 (a highly vulnerable area), whereas Saruchawa Spring is located in S1 (very highly vulnerable). Based on the second method results (recession curve analyses), all three selected springs fall under the (D-type) vulnerability category. As a result, the immediate protection zone was going to be surrounded by the inner protection zone, and both are enclosed within the outer protection zone, which covers the remainder of the catchment area

Design of a piezoelectrically actuated hydrocephalus shunt valve

Hydrocephalus is currently managed by using traditional mechanical passive shunts. Due to their nature, these shunts have fundamental shortcomings including an increase in patient shunt dependency, absence of fault detection, and over drainage due to lack of shunt proactivity. There is a scientific consensus that the way forward to address these issues is through what is termed a smart shunt. The core component of this system is the mechatronic controllable valve. A design of a valve which utilises both the passive nature of the classical valves and the controllability feature of the fully automated valves is presented in this paper. The valve consists of a fluid compartment, a linear spring, and an ultrasonic piezoelectric element. The valve is designed to operate on a 5 V supply, to drain up to 300 mL/h, and it has an operational range between 10 and 20 mmHg. The design produced is considered feasible as it takes into consideration the multiple operation conditions associated with such an implanted system. Graphical Abstract: [Figure not available: see fulltext.]

Dicarbonyl­dichlorido(N,N,N′,N′-tetra­methyl­ethylenediamine)­ruthenium(II)

In the title compound, [RuCl2(C6H16N2)(CO)2], the geometry around the RuII atom is a distorted RuC2N2Cl2 octa­hedron, with pairs of C and Cl atoms trans to each other and the N atoms of the bidentate ligand in a cis conformation. The five-membered chelate ring is puckered on the C—C bond

The Biochemical Assessment of Imported Frozen Chicken and Detection The Effect of Biogenic Amines on The Meat Quality

To assess the quality of imported frozen chicken sold in Sulaimani markets with respect to biogenic amines content and sensory properties, a total of 160 samples of frozen chicken meat belonged to four foreign trademarks were collected in two batches from different parts of Sulaimani city markets. The samples consisted of whole chickens (160 samples- 80 for each batch). HPLC- based detection of Biogenic amines revealed histamine within the acceptable limits in all marks, it ranged 0.00- 0.22 and 0.00- 0.03 mg/ Kg meat in batches 1 and 2 respectively for the four marks of carcasses. Putrescine, Cadaverine, Spermine and Spermidine were within the ranges reported in literatures for good chicken meat quality in all marks, except in DMIS. The biogenic amines indexes for all marks were within the acceptable limits except for DMIS, which significantly differed from the others.  The sensory evaluation (organoleptic evaluation) of carcasses revealed highest scores gained by Gedik for all categories then by Sadia and Frinal, while DMIS had the lowest with the presence of significant differences among marks

Bacteriological Quality of Imported Frozen Chicken in Sulaimani Markets

To study the bacteriological quality of imported frozen chicken meat in Sulaimani markets, a total of 360 samples represented whole chickens (160 samples, 80 for each batch), thighs (120 samples, 60 for each batch) and breasts (80 samples, 40 for each batch) belonged to seven commercial trademarks, distributed on two batches, were tested according to international analytical regulations and guides. The mean values of the total plate count (TPC) in batches 1 and 2 of the whole chicken carcasses ranged 0.540-5.720 ×104 and 0.250-5.720 ×104 CFU/ g meat respectively, in thighs they ranged 1.170- 17.520 and 0.730- 12.500 ×104CFU/ g meat respectively, and  in breast they ranged 0.586- 14.380 and 1.174-11.900×104CFU/ g meat respectively. The psychrophiles count in whole chicken carcasses ranged 1.950- 13.740×104  and  0.900-27.420×104 CFU/ g meat, in thighs they ranged 0.554-8.560 and 0.360- 8.000×104 CFU/ g meat, and in breast ranged 0.734-8.880 and 1.140- 9.360 ×104 CFU/ g meat in batches 1 and 2 respectively.  Psychrotrophes count in whole carcasses ranged 1.964- 14.280 and 1.286- 21.800×104 CFU/ g meat, in thighs they ranged 1.560- 12.640 and 3.42- 7.680 ×104 CFU/ g meat, and in breast ranged 0.770- 13.140 and 1.178- 8.440 ×104 CFU/ g meat in batches 1 and 2 respectively. The most probable number (MPN) of both total coliforms and fecal coliforms in the two batches were less than 1 CFU/ g meat in all samples that inspected. Significant differences were recorded among all marks and between both batches for each mark including the three types of meat while all samples were E. coli O157: H7, coagulase positive staphylococci, and Salmonella free

Global, regional, and national burden of stroke and its risk factors, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]) associated with 19 risk factors, for 204 countries and territories from 1990 to 2019. These estimates were provided for ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and all strokes combined, and stratified by sex, age group, and World Bank country income level. Findings In 2019, there were 12·2 million (95% UI 11·0–13·6) incident cases of stroke, 101 million (93·2–111) prevalent cases of stroke, 143 million (133–153) DALYs due to stroke, and 6·55 million (6·00–7·02) deaths from stroke. Globally, stroke remained the second-leading cause of death (11·6% [10·8–12·2] of total deaths) and the third-leading cause of death and disability combined (5·7% [5·1–6·2] of total DALYs) in 2019. From 1990 to 2019, the absolute number of incident strokes increased by 70·0% (67·0–73·0), prevalent strokes increased by 85·0% (83·0–88·0), deaths from stroke increased by 43·0% (31·0–55·0), and DALYs due to stroke increased by 32·0% (22·0–42·0). During the same period, age-standardised rates of stroke incidence decreased by 17·0% (15·0–18·0), mortality decreased by 36·0% (31·0–42·0), prevalence decreased by 6·0% (5·0–7·0), and DALYs decreased by 36·0% (31·0–42·0). However, among people younger than 70 years, prevalence rates increased by 22·0% (21·0–24·0) and incidence rates increased by 15·0% (12·0–18·0). In 2019, the age-standardised stroke-related mortality rate was 3·6 (3·5–3·8) times higher in the World Bank low-income group than in the World Bank high-income group, and the age-standardised stroke-related DALY rate was 3·7 (3·5–3·9) times higher in the low-income group than the high-income group. Ischaemic stroke constituted 62·4% of all incident strokes in 2019 (7·63 million [6·57–8·96]), while intracerebral haemorrhage constituted 27·9% (3·41 million [2·97–3·91]) and subarachnoid haemorrhage constituted 9·7% (1·18 million [1·01–1·39]). In 2019, the five leading risk factors for stroke were high systolic blood pressure (contributing to 79·6 million [67·7–90·8] DALYs or 55·5% [48·2–62·0] of total stroke DALYs), high bodymass index (34·9 million [22·3–48·6] DALYs or 24·3% [15·7–33·2]), high fasting plasma glucose (28·9 million [19·8–41·5] DALYs or 20·2% [13·8–29·1]), ambient particulate matter pollution (28·7 million [23·4–33·4] DALYs or 20·1% [16·6–23·0]), and smoking (25·3 million [22·6–28·2] DALYs or 17·6% [16·4–19·0]). Interpretation The annual number of strokes and deaths due to stroke increased substantially from 1990 to 2019, despite substantial reductions in age-standardised rates, particularly among people older than 70 years. The highest age-standardised stroke-related mortality and DALY rates were in the World Bank low-income group. The fastest growing risk factor for stroke between 1990 and 2019 was high body-mass index. Without urgent implementation of effective primary prevention strategies, the stroke burden will probably continue to grow across the world, particularly in low-income countries

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019 : a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines

Efficacy and safety of empagliflozin in type 2 diabetes mellitus Saudi patients as add-on to antidiabetic therapy: a prospective, open-label, observational study

The Saudi Food and Drug Authority (SFDA) approved sodium-glucose cotransporter-2 (SGLT2) inhibitors in 2018. The efficacy and safety of empagliflozin (EMPA) have been confirmed in the U.S., Europe, and Japan for patients with type 2 diabetes mellitus (T2DM); however, analogous evidence is lacking for Saudi T2DM patients. Therefore, the current study aimed to assess the efficacy and safety of EMPA in Saudi patients (n = 256) with T2DM. This is a 12-week prospective, open-label, observational study. Adult Saudi patients with T2DM who had not been treated with EMPA before enrolment were eligible. The exclusion criteria included T2DM patients less than 18 years of age, adults with type one diabetes, pregnant women, paediatric population. The results related to efficacy included a significant decrease in haemoglobin A1c (HbA1c) (adjusted mean difference −0.93% [95% confidence interval (CI) −0.32, −1.54]), significant improvements in fasting plasma glucose (FPG) (−2.28 mmol/L [95% CI −2.81, −1.75]), and a reduction in body weight (−0.874 kg [95% CI −4.36, −6.10]) following the administration of 25 mg of EMPA once daily as an add-on to ongoing antidiabetic therapy after 12 weeks. The primary safety endpoints were the change in the mean blood pressure (BP) values, which indicated significantly reduced systolic and diastolic BP (−3.85 mmHg [95% CI −6.81, −0.88] and −0.06 mmHg [95% CI −0.81, −0.88], respectively) and pulse rate (−1.18 [95% CI −0.79, −3.15]). In addition, kidney function was improved, with a significant reduction in the urine albumin/creatinine ratio (UACR) (−1.76 mg/g [95% CI −1.07, −34.25]) and a significant increase in the estimated glomerular filtration rate (eGFR) (3.54 mL/min/1.73 m2 [95% CI 2.78, 9.87]). Furthermore, EMPA reduced aminotransferases (ALT) in a pattern (reduction in ALT > AST). The adjusted mean difference in the change in ALT was −2.36 U/L [95% CI −1.031, −3.69], while it was −1.26 U/L [95% CI −0.3811, −2.357] for AST and −1.98 U/L [95% CI −0.44, −3.49] for GGT. Moreover, in the EMPA group, serum high-density lipoprotein (HDL) significantly increased (0.29 mmol/L [95% CI 0.74, 0.15]), whereas a nonsignificant increase was seen in low-density lipoprotein (LDL) (0.01 mmol/L [95% CI 0.19, 0.18]) along with a significant reduction in plasma triglyceride (TG) levels (−0.43 mmol/L [95% CI −0.31, −1.17]). Empagliflozin once daily is an efficacious and tolerable strategy for treating Saudi patients with insufficiently controlled T2DM as an add-on to ongoing antidiabetic therapy